| Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia I Aldoss, D Yang, A Aribi, H Ali, K Sandhu, MM Al Malki, M Mei, A Salhotra, ... Haematologica 103 (9), e404, 2018 | 239 | 2018 |
| Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial M Jagasia, MA Perales, MA Schroeder, H Ali, NN Shah, YB Chen, S Fazal, ... Blood, The Journal of the American Society of Hematology 135 (20), 1739-1749, 2020 | 237 | 2020 |
| Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia B Zhang, LXT Nguyen, L Li, D Zhao, B Kumar, H Wu, A Lin, F Pellicano, ... Nature medicine 24 (4), 450-462, 2018 | 137 | 2018 |
| Phase I trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed/refractory acute leukemia A Stein, J Palmer, NC Tsai, MM Al Malki, I Aldoss, H Ali, A Aribi, L Farol, ... Biology of Blood and Marrow transplantation 23 (4), 618-624, 2017 | 96 | 2017 |
| Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology AT Gerds, J Gotlib, H Ali, P Bose, A Dunbar, A Elshoury, TI George, ... Journal of the National Comprehensive Cancer Network 20 (9), 1033-1062, 2022 | 93* | 2022 |
| Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia I Aldoss, D Yang, R Pillai, JF Sanchez, M Mei, A Aribi, H Ali, K Sandhu, ... American journal of hematology 94 (10), E253, 2019 | 86 | 2019 |
| Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients H Ali, D Ngo, A Aribi, S Arslan, S Dadwal, G Marcucci, R Nakamura, ... Transplantation and cellular therapy 27 (11), 938. e1-938. e6, 2021 | 79 | 2021 |
| A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease MA Schroeder, HJ Khoury, M Jagasia, H Ali, GJ Schiller, K Staser, J Choi, ... Blood Advances 4 (8), 1656-1669, 2020 | 79 | 2020 |
| Ruxolitinib as salvage therapy for chronic graft-versus-host disease B Modi, M Hernandez-Henderson, D Yang, J Klein, S Dadwal, E Kopp, ... Biology of Blood and Marrow Transplantation 25 (2), 265-269, 2019 | 76 | 2019 |
| Survival following allogeneic transplant in patients with myelofibrosis K Gowin, K Ballen, KW Ahn, ZH Hu, H Ali, MO Arcasoy, R Devlin, ... Blood advances 4 (9), 1965-1973, 2020 | 71 | 2020 |
| Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents I Aldoss, S Dadwal, J Zhang, B Tegtmeier, M Mei, S Arslan, MM Al Malki, ... Blood advances 3 (23), 4043-4049, 2019 | 64 | 2019 |
| MIPSS70+ v2. 0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen H Ali, I Aldoss, D Yang, S Mokhtari, S Khaled, A Aribi, M Afkhami, ... Blood advances 3 (1), 83-95, 2019 | 54 | 2019 |
| Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in … I Aldoss, T Stiller, NC Tsai, JY Song, T Cao, NA Bandara, A Salhotra, ... haematologica 103 (10), 1662, 2018 | 48 | 2018 |
| Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia KS Sandhu, S Dadwal, D Yang, M Mei, J Palmer, A Salhotra, M Al Malki, ... Biology of Blood and Marrow Transplantation 26 (12), e322-e327, 2020 | 39 | 2020 |
| Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant MM Al Malki, NC Tsai, J Palmer, S Mokhtari, W Tsai, T Cao, H Ali, ... Blood advances 5 (12), 2650-2659, 2021 | 37 | 2021 |
| Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia I Aldoss, J Zhang, M Mei, MM Al Malki, S Arslan, D Ngo, A Aribi, H Ali, ... American journal of hematology 95 (10), 1193-1199, 2020 | 34 | 2020 |
| Ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute graft-vs-host disease: results from the phase 2 REACH1 trial M Jagasia, H Ali, MA Schroeder, NN Shah, YB Chen, F Dawkins, ... Biology of Blood and Marrow Transplantation 25 (3), S52, 2019 | 28 | 2019 |
| 2021 update on allogeneic hematopoietic stem cell transplant for myelofibrosis: a review of current data and applications on risk stratification and management H Ali, A Bacigalupo American Journal of Hematology 96 (11), 1532-1538, 2021 | 26 | 2021 |
| Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status I Aldoss, A Pham, SM Li, K Gendzekhadze, M Afkhami, M Telatar, H Hong, ... Haematologica 102 (12), 2030, 2017 | 26 | 2017 |
| Results from a phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate, or high risk, relapsed/refractory myelofibrosis N Pemmaraju, V Gupta, H Ali, A Yacoub, ES Wang, S Lee, GJ Schiller, ... Blood 134, 558, 2019 | 25 | 2019 |
